Core Points - The Shenzhen Stock Exchange announced on December 8 that due to the adjustment of the Hang Seng Composite Midcap Index, the list of eligible securities for the Hong Kong Stock Connect will be updated, effective from December 8, 2025 [1] Group 1: Company Adjustments - Four companies have been added to the Hong Kong Stock Connect: FWD Group (01828), Aux Group (02580), Sinopharm Group (02591), and Chery Automobile (09973) [1][3] - The adjustment reflects the ongoing changes in the market and the inclusion of mid-cap stocks in the investment framework [1]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The company, Silver诺医药-B (02591), has successfully included its core product, Isuparaglutide α, in the latest version of China's National Medical Insurance Drug List (2025 edition) for the treatment of Type 2 Diabetes (T2D) [1] Group 1 - The inclusion of Isuparaglutide α in the National Medical Insurance Drug List is a significant milestone for the company [1] - The updated National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]

Core Viewpoint - The announcement highlights that the core product, Isuparaglutide α, has been successfully included in the latest version of China's National Medical Insurance Drug List (2025 edition), effective from January 1, 2026, for the treatment of Type 2 Diabetes (T2D) [1][2]. Group 1: Product Details - Isuparaglutide α is the first domestically developed long-acting GLP-1 receptor agonist in China, approved for monotherapy and in combination with metformin for T2D treatment [1]. - Clinical studies have demonstrated that Isuparaglutide α has a rapid onset, strong and lasting efficacy, a long half-life, and good safety profile [1]. Group 2: Clinical Trial Results - In a Phase III clinical trial, T2D patients receiving Isuparaglutide α monotherapy (3.0 mg) showed a reduction in HbA1c levels by 1.1% after 4 weeks of treatment [1]. - In another randomized, double-blind, placebo-controlled Phase III trial, Isuparaglutide α at doses of 1.0 mg and 3.0 mg resulted in significant reductions in HbA1c levels of 1.7% and 2.2% respectively at week 24, demonstrating both statistical and clinical significance [1]. Group 3: Pharmacokinetics and Safety - Isuparaglutide α has an average half-life of 204 hours, allowing for low dosing frequency in long-term disease management [2]. - The safety profile of Isuparaglutide α is favorable, with no observed cases of drug-related grade 2 or higher hypoglycemia in clinical trials [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」）作出，以向本公司股東 （「股東」）及有意投資者告知有關本公司近期的業務發展。 自願性公告 本公司核心產品納入《國家醫保藥品目錄》 － 依蘇帕格魯肽α安全性良好。在依蘇帕格魯肽α的臨床試驗中，均未觀察到藥 物相關2級或以上低血糖症案例。 有關本集團核心產品（即依蘇帕格魯肽α）的進一步詳情，請參閱本公司日期為 2025年8月7日的招股章程。 承董事會命 廣州銀諾醫藥集團股份有限公司 董事長 WANG QINGHUA博士 中華人民共和國，上海，2025年12月7日 董事會欣然宣佈，本集團核心產品（即依蘇帕格魯肽α）已成功納入中國最新版 《國家醫保藥品目錄》（2025年版） ...

Core Viewpoint - Silver诺医药-B (02591) has seen its stock price increase by over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The transaction volume reached 764.33 million HKD [1] Group 2: Market Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index as part of the quarterly review results [1] - The change will take effect on December 8, 2025 [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease [1] - All drugs are self-developed and possess global intellectual property rights, with a comprehensive global research and market layout [1]

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 5%, marking three consecutive days of gains, currently trading at 43.42 HKD with a transaction volume of 7.6433 million HKD [1] Group 1: Stock Performance - The stock price of Silver诺医药-B has risen by 5.03% [1] - The current trading price is 43.42 HKD [1] - The trading volume reached 7.6433 million HKD [1] Group 2: Index Inclusion - Silver诺医药 has been included in the Hang Seng Composite Index, with changes effective from December 8, 2025 [1] - This inclusion is part of the quarterly review results of the Hang Seng Index series [1] Group 3: Company Overview - Silver诺医药 is focused on the field of metabolic diseases [1] - The company has multiple innovative drug development pipelines targeting diabetes, obesity, and non-alcoholic fatty liver disease, all of which are self-developed [1] - The company holds global intellectual property rights and has a comprehensive global research and market layout [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - The company, Silver诺医药-B (02591), announced that on December 1, 2025, it, along with its wholly-owned subsidiary Silver诺技术, will subscribe to a structured deposit product from 宁波银行 for a total consideration of RMB 125 million, which is equivalent to its total principal amount [1]

Core Viewpoint - Silver诺医药-B (02591.HK) announced the subscription of a structured deposit product from Ningbo Bank for a total consideration of RMB 125 million, which represents the total principal amount [1] Group 1 - The company, along with its wholly-owned subsidiary Silver诺技术, will subscribe to the structured deposit product [1] - The total investment amount for the structured deposit product is RMB 125 million [1]